查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880519

2032年肾臟病治疗市场预测：按疾病类型、药物类别、给药途径、通路、最终用户和地区分類的全球分析

Preeclampsia Drugs Market Forecasts to 2032 - Global Analysis By Condition Type (Mild Preeclampsia and Severe Preeclampsia), Drug Class, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球肾臟病治疗市场价值将达到 12.5 亿美元，到 2032 年将达到 27.7 亿美元，在预测期内的复合年增长率为 12.0%。

妊娠毒血症）和皮质类固醇（用于促进胎儿肺部成熟）。虽然这些药物不能治癒妊娠毒血症，治疗方法它们可以帮助控制严重的症状，并稳定病情，直到分娩成为最安全的选择。

根据美国心臟协会的记录，妊娠毒血症影响约 5-7% 的孕妇，是发病率和死亡率最高的疾病。在全球范围内，该疾病每年导致超过 7 万名孕产妇死亡和超过 50 万名胎儿死亡。

风险因素增加

随着诊断意识的提高，越来越多的病例在早期阶段被发现，增加了对有效药物治疗的需求。医疗系统正在采用先进的筛检工具，例如生物标记检测和基于人工智慧的风险预测模型。这些技术帮助临床医生更早发现孕产妇併发症，增加了预防性和治疗性药物的使用。标靶治疗和个人化治疗通讯协定的创新进一步推动了市场扩张。随着生活方式相关风​​险因素在全球范围内日益受到关注，对可靠的妊娠毒血症管理解决方案的需求持续增长。

缺乏标准化的治疗通讯协定

不同地区诊断标准的差异导致治疗方法不一致，并造成干预延误。新兴的数位健康工具和临床决策支援系统旨在简化通讯协定，但尚未普遍应用。小规模医疗机构面临训练不足和缺乏先进孕产妇监测技术等问题。这种不一致延缓了新药製剂的上市，并阻碍了临床试验的标准化。因此，缺乏明确的指南持续限制市场成长。

预防疗法的开发

製药公司正投资研发低剂量阿斯匹灵製剂、抗氧化剂和新兴生物製剂，以预防疾病的发生。基因组学和预测分析技术的进步使得在怀孕早期识别高风险孕妇成为可能。这些进步使得利用穿戴式孕妇健康追踪器和人工智慧预测平台进行个人化预防性治疗成为可能。目前，一些针对内皮功能障碍和胎盘异常的极具前景的在研药物正在进行临床试验。随着预防性治疗在全球日益受到关注，市场有望迎来显着成长。

来自非药物疗法的竞争压力

非药物疗法，例如饮食调整、生活方式介入和数位化产前监测工具，正逐渐成为药物治疗的替代方案。穿戴式装置和远端医疗平台无需药物即可实现持续的风险评估。随着患者偏好转向非侵入性治疗方案，製药公司面临激烈的竞争压力。减少对药物治疗依赖的综合产前护理模式正变得越来越普遍，为了应对这一趋势，各公司正在将数位化工具与药物治疗相结合，以保持市场竞争力。

新冠疫情的影响：

新冠疫情扰乱了产前保健，导致妊娠毒血症症诊断延迟，病情加重。封锁措施影响了药品供应链，造成生产延误，并导致产前药物暂时短缺。然而，这种情况加速了远距产前保健所需的数位监测工具的普及。远端医疗平台和连网血压监测设备已成为产前保健流程中不可或缺的一部分。疫情后，医疗保健产业正优先建构具有韧性的供应链网路和混合式产前保健模式。

预计在预测期内，重度妊娠毒血症症细分市场将占据最大的市场份额。

由于住院率上升和硫酸镁降血压疗法的使用增加，预计在预测期内，重妊娠毒血症症细分市场将占据最大的市场份额。加护治疗医学的进步和病患监测技术的改进正在推动该细分市场的扩张。人工智慧驱动的胎儿健康评估工具的日益普及正在提升重症病例的决策水准。针对内皮修復和胎盘功能障碍的新型候选药物的出现进一步推动了该细分市场的成长。临床指引也更加重视重症病例的积极治疗，导致药物消费量增加。

预计在预测期内，专科诊所细分市场将呈现最高的复合年增长率。

预计在预测期内，专科诊所领域将实现最高成长率，这主要得益于母胎医学服务覆盖范围的扩大。这些诊所正在迅速采用先进的诊断工具，例如多普勒成像、生物感测器和预测分析平台。高危险妊娠计画的扩展也促进了标靶药物治疗的使用。远距医疗和远距胎儿监护的整合正在提升专科医疗机构的护理连续性。专科诊所专注于个人化孕产妇护理，并正大力投资创新治疗方法和数位化工具。

占比最大的地区：

由于出生率上升和妊娠併发症增多，预计亚太地区将在预测期内占据最大的市场份额。中国、印度、日本和东南亚各国政府正在加大投入，以实现孕产妇保健系统的现代化。包括生物标记筛检和基于人工智慧的孕产妇监测在内的先进诊断技术在该地区的应用正在加速。製药公司正透过合作、临床试验和本地生产设施扩大其市场份额。不断加强的宣传活动正在促进妊娠毒血症的早期诊断和治疗。

预计年复合成长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于其强大的技术领先地位和先进孕产妇护理解决方案的快速普及。该地区受益于以生物製药、标靶治疗和个人化医疗为重点的强劲研发投入。医院和诊所正越来越多地采用物联网赋能的孕产妇监测设备和人工智慧驱动的诊断工具。监管机构正致力于简化创新孕产妇药物的核准流程。美国和加拿大民众对高风险怀孕的日益关注，正在推动对先进治疗方法的需求。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，对主要国家的市场规模进行估算和预测，併计算复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要企业的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 介绍
  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球肾臟病治疗市场（依病症类型划分）

  • 介绍
  • 轻度子痫前症
  • 重度子痫前症

6. 全球肾臟病药物市场（依药物类别划分）

  • 介绍
  • 抗高血压药物
  • 抗惊厥药
  • 皮质类固醇
  • 其他药物

7. 全球肾臟病药物市场（依给药途径划分）

  • 介绍
  • 口服
  • 肠外

8. 全球肾臟病药物市场（依通路划分）

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

9. 全球肾臟病药物市场（依最终用户划分）

  • 介绍
  • 医院
  • 诊断中心
  • 专科诊所
  • 其他最终用户

10. 全球肾臟病药物市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章：企业概况

  • Thermo Fisher Scientific Inc.
  • AbbVie Inc.
  • Baxter International Inc.
  • Johnson & Johnson
  • Bayer AG
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: SMRC32555

According to Stratistics MRC, the Global Preeclampsia Drugs Market is accounted for $1.25 billion in 2025 and is expected to reach $2.77 billion by 2032 growing at a CAGR of 12.0% during the forecast period. Preeclampsia drugs refer to medicines designed to control and treat preeclampsia, a condition in pregnancy marked by elevated blood pressure and potential organ damage. These treatments regulate blood pressure, lower seizure risk, and protect maternal and fetal health. Key options include blood-pressure-lowering drugs, magnesium sulfate for seizure prevention, and corticosteroids to enhance fetal lung maturity. Although they cannot eliminate preeclampsia, these medications help manage critical symptoms and maintain stability until delivery becomes the safest option.

According to the records of American Heart Association, Inc., the greatest morbidity and mortality, preeclampsia affects around 5% to 7% of all pregnant women; though, it is responsible for over 70, 000 maternal deaths and 500,000 fetal deaths worldwide each year.

Market Dynamics:

Driver:

Increasing prevalence of risk factors

As diagnostic awareness grows, more cases are being identified early, increasing the need for effective pharmacological interventions. Healthcare systems are adopting advanced screening tools such as biomarker-based tests and AI-enabled risk prediction models. These technologies are helping clinicians detect maternal complications sooner, driving the uptake of preventive and therapeutic drugs. Innovations in targeted therapies and personalized treatment protocols are further accelerating market expansion. With lifestyle-related risk factors intensifying globally, demand for reliable preeclampsia management solutions continues to grow.

Restraint:

Lack of standardized treatment protocols

Variability in diagnostic criteria across regions leads to inconsistent therapeutic approaches and delayed intervention. Emerging digital health tools and clinical decision-support systems aim to streamline protocols but are still not uniformly adopted. Smaller healthcare facilities struggle with limited training and access to advanced maternal monitoring technologies. This inconsistency slows the adoption of new drug formulations and hinders clinical trial standardization. As a result, the lack of clear guidelines continues to restrain market growth despite ongoing research.

Opportunity:

Development of preventive therapies

Pharmaceutical companies are investing in low-dose aspirin formulations, antioxidants, and emerging biologics designed to reduce disease onset. Advances in genomics and predictive analytics are helping identify high-risk patients earlier in pregnancy. These developments are enabling personalized preventive regimens supported by wearable maternal health trackers and AI-based prediction platforms. Several promising pipeline drugs are undergoing trials that target endothelial dysfunction and placental abnormalities. As preventive therapy gains global traction, the market is poised for significant expansion.

Threat:

Competitive pressure from non-pharmacological interventions

Non-drug approaches such as dietary modification, lifestyle programs, and digital maternal monitoring tools are increasingly offering alternatives to pharmacological treatment. Wearable devices and telehealth platforms are enabling continuous risk assessment without medication. As patient preference shifts toward non-invasive options, drug manufacturers face heightened competitive pressure. Integrative maternal care models are becoming prevalent, reducing reliance on pharmacotherapy alone. These trends are prompting companies to integrate digital tools with drug therapies to maintain market relevance.

Covid-19 Impact:

The Covid-19 pandemic disrupted prenatal care, leading to delayed diagnosis and increased severity of preeclampsia cases. Lockdowns affected drug supply chains and slowed manufacturing, causing temporary shortages of maternal medications. However, the situation accelerated adoption of digital monitoring tools, enabling remote prenatal assessments. Telemedicine platforms and connected blood-pressure monitoring devices became integral to maternal care workflows. Post-pandemic, healthcare systems are prioritizing resilient supply networks and hybrid maternal care models.

The severe preeclampsia segment is expected to be the largest during the forecast period

The severe preeclampsia segment is expected to account for the largest market share during the forecast period, due to rising hospitalization rates and increasing use of magnesium sulfate and antihypertensive therapies. Advancements in critical-care pharmacology and improved inpatient monitoring technologies are supporting this segment's expansion. The growing availability of AI-enabled fetal health assessment tools is enhancing decision-making in severe cases. Emerging drug candidates targeting endothelial repair and placental dysfunction are further strengthening segment growth. Clinical guidelines also prioritize aggressive management of severe cases, increasing drug consumption.

The specialty clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate, due to expanding access to maternal-fetal medicine services. These clinics are rapidly adopting advanced diagnostic tools such as Doppler imaging, bio-sensors, and predictive analytics platforms. Growth in high-risk pregnancy programs is increasing the use of targeted drug regimens. The integration of tele-consultation and remote fetal monitoring is enhancing treatment continuity within specialty settings. With a focus on personalized maternal care, specialty clinics are investing in innovative therapeutics and digital tools.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rising birth rates and increasing prevalence of pregnancy-related complications. Governments across China, India, Japan, and Southeast Asia are investing in modernizing maternal healthcare systems. Adoption of advanced diagnostic technologies, including biomarker screening and AI-based maternal monitoring, is accelerating in the region. Pharmaceutical companies are expanding their presence through partnerships, clinical trials, and regional production facilities. Growing awareness campaigns are encouraging early diagnosis and treatment of preeclampsia.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong technological leadership and rapid adoption of advanced maternal care solutions. The region benefits from robust R&D investments focusing on biologics, targeted therapies, and personalized medicine. Hospitals and clinics are integrating IoT-enabled maternal monitoring devices and AI-powered diagnostic tools. Regulatory agencies are working toward streamlined approval pathways for innovative maternal drugs. Rising awareness of high-risk pregnancies in the U.S. and Canada is fueling demand for advanced treatments.

Key players in the market

Some of the key players in Preeclampsia Drugs Market include Thermo Fi, AbbVie Inc., Baxter International, Johnson & Johnson, Bayer AG, AstraZeneca, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline, Teva Pharmaceuticals, Takeda Pharmaceuticals.

Key Developments:

In November 2025, Pfizer Inc. announced the completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transaction it's a deliberate investment in the future of medicine.

In October 2025, Thermo Fisher Scientific announced a new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden. The partnership aims to leverage the combined expertise of Thermo Fisher and AstraZeneca to drive innovation and strengthen the life science ecosystem.

Condition Types Covered:

  • Mild Preeclampsia
  • Severe Preeclampsia

Drug Classes Covered:

  • Antihypertensives
  • Anticonvulsants
  • Corticosteroids
  • Other Therapies

Route of Administrations Covered:

  • Oral
  • Parenteral

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preeclampsia Drugs Market, By Condition Type

  • 5.1 Introduction
  • 5.2 Mild Preeclampsia
  • 5.3 Severe Preeclampsia

6 Global Preeclampsia Drugs Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antihypertensives
  • 6.3 Anticonvulsants
  • 6.4 Corticosteroids
  • 6.5 Other Therapies

7 Global Preeclampsia Drugs Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral

8 Global Preeclampsia Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Preeclampsia Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Centers
  • 9.4 Specialty Clinics
  • 9.5 Other End Users

10 Global Preeclampsia Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 AbbVie Inc.
  • 12.3 Baxter International Inc.
  • 12.4 Johnson & Johnson
  • 12.5 Bayer AG
  • 12.6 AstraZeneca plc
  • 12.7 Merck & Co., Inc.
  • 12.8 Sanofi S.A.
  • 12.9 F. Hoffmann-La Roche Ltd.
  • 12.10 Novartis AG
  • 12.11 Pfizer Inc.
  • 12.12 Eli Lilly and Company
  • 12.13 GlaxoSmithKline plc
  • 12.14 Teva Pharmaceutical Industries Ltd.
  • 12.15 Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1 Global Preeclampsia Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Preeclampsia Drugs Market Outlook, By Condition Type (2024-2032) ($MN)
  • Table 3 Global Preeclampsia Drugs Market Outlook, By Mild Preeclampsia (2024-2032) ($MN)
  • Table 4 Global Preeclampsia Drugs Market Outlook, By Severe Preeclampsia (2024-2032) ($MN)
  • Table 5 Global Preeclampsia Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 6 Global Preeclampsia Drugs Market Outlook, By Antihypertensives (2024-2032) ($MN)
  • Table 7 Global Preeclampsia Drugs Market Outlook, By Anticonvulsants (2024-2032) ($MN)
  • Table 8 Global Preeclampsia Drugs Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 9 Global Preeclampsia Drugs Market Outlook, By Other Therapies (2024-2032) ($MN)
  • Table 10 Global Preeclampsia Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 11 Global Preeclampsia Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 12 Global Preeclampsia Drugs Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 13 Global Preeclampsia Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 14 Global Preeclampsia Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 15 Global Preeclampsia Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 16 Global Preeclampsia Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 17 Global Preeclampsia Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 18 Global Preeclampsia Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 19 Global Preeclampsia Drugs Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 20 Global Preeclampsia Drugs Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 21 Global Preeclampsia Drugs Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.